A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Clinical trial NCT07744126 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07744126
- Sponsor
- AbbVie
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-30
- Primary completion
- 2029-10-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.